Skip to main content
Premium Trial:

Request an Annual Quote

GATC Will Use 454's GS20 to Sequence DNA and Transcriptomes, and Analyze Mutations

NEW YORK (GenomeWeb News) — GATC Biotech will use 454 Life Sciences’ genome sequencing technology for its sequencing and analysis business, GATC said today.
 
GATC, based in Konstanz, Germany, said that by adapting 454’s technology with traditional Sanger technology it can cut the sequencing and analysis time in half and reduce costs.
 
The company also said it will use 454’s instrument to sequence whole transcriptomes and for in-depth analyses of rare mutations.
 
GATC said using 454’s technology has boosted its own sequencing capacity to 15.6 gigabases per year.
 
Financial terms of the agreement were not disclosed.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.